My Account Log in

3 options

Advancing progress in the development of combination cancer therapies with immune checkpoint inhibitors : proceedings of a workshop / Erin Balogh and Sharyl J. Nass, rapporteurs ; National Cancer Policy Forum [and three others].

EBSCOhost Academic eBook Collection (North America) Available online

View online

NCBI Bookshelf Available online

View online

National Academies Press Available online

View online
Format:
Book
Author/Creator:
Balogh, Erin, author.
Nass, Sharyl J., author.
Contributor:
National Cancer Policy Forum (U.S.), contributor.
Language:
English
Subjects (All):
Chemotherapy, Combination--Congresses.
Chemotherapy, Combination.
Physical Description:
1 online resource (xx, 67 pages) : illustrations
Place of Publication:
Washington, District of Columbia : The National Academies Press, [2019]
Summary:
In recent years, significant progress has been made in the clinical development and use of various types of cancer immunotherapy, all of which rely on the immune system to fight cancer. The majority of new cancer drug applications submitted to the Food and Drug Administration (FDA) are for immunotherapies or combinations involving immunotherapies. One type of immunotherapy is an immune checkpoint inhibitor. Cells in the human body have proteins that regulate the immune system response to foreign invaders (e.g., cancer cells, microorganisms). However, cancer cells can coopt these "checkpoint" proteins and thwart the immune system's ability to recognize and attack cancer cells. To help promote an immune response to cancer, researchers have developed immune checkpoint inhibitors that enable T-cells to recognize cancer cells as foreign and to prevent deactivation of an immune system response. To examine the challenges and opportunities to develop combination cancer therapies that include immune checkpoint inhibitors, the National Cancer Policy Forum held a workshop on July 16-17, 2018, in Washington, DC. This workshop convened stakeholders with a broad range of expertise, including cancer researchers, clinicians, patient advocates, and representatives from industry, academia, and government. This publication summarizes the presentations and discussions from the workshop.
Notes:
Description based on print version record.
ISBN:
0-309-49089-8
0-309-49087-1

The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.

Find

Home Release notes

My Account

Shelf Request an item Bookmarks Fines and fees Settings

Guides

Using the Find catalog Using Articles+ Using your account